AcelRx to Host Second Quarter 2020 Financial Results Call and Webcast on Monday, August 10th, 2020

Rhea-AI Summary

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) will release its second quarter financial results on August 10, 2020, after market close. A conference call and webcast hosted by management will occur at 4:30 p.m. ET on the same day to review the results and provide updates. The webcast can be accessed via the company's website. AcelRx specializes in innovative therapies, with its approved product, DSUVIA, indicated for acute pain management in medically supervised settings, and its candidate, Zalviso, under development.

Positive

• AcelRx has an approved product, DSUVIA, for acute pain management in the U.S.
• Zalviso, a candidate product for patient-controlled analgesia, is approved in Europe.

Negative

• Zalviso is still investigational and not approved in the U.S.

REDWOOD CITY, Calif., Aug. 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 10, 2020. AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on August 10, 2020 to discuss the financial results and provide an update on the company's business.

The webcast is accessible by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page. The webcast will be accompanied by a slide presentation.  A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at www.acelrx.com.

Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers, or (412) 902-4204 for international callers.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA®(sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is an investigational drug and not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-to-host-second-quarter-2020-financial-results-call-and-webcast-on-monday-august-10th-2020-301104943.html

SOURCE AcelRx Pharmaceuticals, Inc.

FAQ

When will AcelRx release its second quarter financial results?

AcelRx will release its second quarter financial results on August 10, 2020, after market close.

What time is the AcelRx conference call about financial results?

The conference call hosted by AcelRx management will take place at 4:30 p.m. ET on August 10, 2020.

Where can I watch the AcelRx financial results webcast?

The webcast can be accessed via AcelRx's website at www.acelrx.com.

What products does AcelRx Pharmaceuticals have on the market?

AcelRx has DSUVIA approved in the U.S. for acute pain management, and Zalviso is approved in Europe.